536 related articles for article (PubMed ID: 29264776)
1. Comparing and transforming PROMIS utility values to the EQ-5D.
Hartman JD; Craig BM
Qual Life Res; 2018 Mar; 27(3):725-733. PubMed ID: 29264776
[TBL] [Abstract][Full Text] [Related]
2. Mapping PROMIS Global Health Items to EuroQol (EQ-5D) Utility Scores Using Linear and Equipercentile Equating.
Thompson NR; Lapin BR; Katzan IL
Pharmacoeconomics; 2017 Nov; 35(11):1167-1176. PubMed ID: 28710740
[TBL] [Abstract][Full Text] [Related]
3. Choice Defines QALYs: A US Valuation of the EQ-5D-5L.
Craig BM; Rand K
Med Care; 2018 Jun; 56(6):529-536. PubMed ID: 29668646
[TBL] [Abstract][Full Text] [Related]
4. Evidence on the relationship between PROMIS-29 and EQ-5D: a literature review.
Pan T; Mulhern B; Viney R; Norman R; Tran-Duy A; Hanmer J; Devlin N
Qual Life Res; 2022 Jan; 31(1):79-89. PubMed ID: 34181154
[TBL] [Abstract][Full Text] [Related]
5. Parallel Valuation: A Direct Comparison of EQ-5D-3L and EQ-5D-5L Societal Value Sets.
Law EH; Pickard AS; Xie F; Walton SM; Lee TA; Schwartz A
Med Decis Making; 2018 Nov; 38(8):968-982. PubMed ID: 30403577
[TBL] [Abstract][Full Text] [Related]
6. A comparison of the EQ-5D-3L and ICECAP-O in an older post-acute patient population relative to the general population.
Couzner L; Crotty M; Norman R; Ratcliffe J
Appl Health Econ Health Policy; 2013 Aug; 11(4):415-25. PubMed ID: 23807538
[TBL] [Abstract][Full Text] [Related]
7. Mapping the FACT-B Instrument to EQ-5D-3L in Patients with Breast Cancer Using Adjusted Limited Dependent Variable Mixture Models versus Response Mapping.
Gray LA; Wailoo AJ; Hernandez Alava M
Value Health; 2018 Dec; 21(12):1399-1405. PubMed ID: 30502783
[TBL] [Abstract][Full Text] [Related]
8. Interchangeability of the EQ-5D and the SF-6D, and comparison of their psychometric properties in a spinal postoperative Spanish population.
Selva-Sevilla C; Ferrara P; Gerónimo-Pardo M
Eur J Health Econ; 2020 Jun; 21(4):649-662. PubMed ID: 32065301
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the psychometric properties of the EQ-5D-3L and SF-6D in the general population of Chengdu city in China.
Zhao L; Liu X; Liu D; He Y; Liu Z; Li N
Medicine (Baltimore); 2019 Mar; 98(11):e14719. PubMed ID: 30882636
[TBL] [Abstract][Full Text] [Related]
10. Converting Parkinson-Specific Scores into Health State Utilities to Assess Cost-Utility Analysis.
Chen G; Garcia-Gordillo MA; Collado-Mateo D; Del Pozo-Cruz B; Adsuar JC; Cordero-Ferrera JM; Abellán-Perpiñán JM; Sánchez-Martínez FI
Patient; 2018 Dec; 11(6):665-675. PubMed ID: 29876865
[TBL] [Abstract][Full Text] [Related]
11. Comparison of contemporaneous responses for EQ-5D-3L and Minnesota Living with Heart Failure; a case for disease specific multiattribute utility instrument in cardiovascular conditions.
Kularatna S; Byrnes J; Chan YK; Carrington MJ; Stewart S; Scuffham PA
Int J Cardiol; 2017 Jan; 227():172-176. PubMed ID: 27865116
[TBL] [Abstract][Full Text] [Related]
12. Mapping the EORTC QLQ-C30 to EQ-5D-3L in patients with breast cancer.
Gray LA; Hernandez Alava M; Wailoo AJ
BMC Cancer; 2021 Nov; 21(1):1237. PubMed ID: 34794404
[TBL] [Abstract][Full Text] [Related]
13. Assessing outcomes for cost-utility analysis in mental health interventions: mapping mental health specific outcome measure GHQ-12 onto EQ-5D-3L.
Lindkvist M; Feldman I
Health Qual Life Outcomes; 2016 Sep; 14(1):134. PubMed ID: 27644119
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the EQ-5D 3L and the SF-6D (SF-36) contemporaneous utility scores in patients with chronic kidney disease in Sri Lanka: a cross-sectional survey.
Kularatna S; Senanayake S; Gunawardena N; Graves N
BMJ Open; 2019 Feb; 9(2):e024854. PubMed ID: 30772857
[TBL] [Abstract][Full Text] [Related]
15. Utilities Estimated from PROMIS Scales for Cost-Effectiveness Analyses in Stroke.
Thompson NR; Lapin BR; Katzan IL
Med Decis Making; 2023 Aug; 43(6):704-718. PubMed ID: 37401739
[TBL] [Abstract][Full Text] [Related]
16. Generating EQ-5D-3L Utility Scores from the Dermatology Life Quality Index: A Mapping Study in Patients with Psoriasis.
Davison NJ; Thompson AJ; Turner AJ; Longworth L; McElhone K; Griffiths CEM; Payne K;
Value Health; 2018 Aug; 21(8):1010-1018. PubMed ID: 30098665
[TBL] [Abstract][Full Text] [Related]
17. Comparison of EQ-5D-5L and SPVU-5D for measuring quality of life in patients with venous leg ulcers in an Australian setting.
Cheng Q; Kularatna S; Lee XJ; Graves N; Pacella RE
Qual Life Res; 2019 Jul; 28(7):1903-1911. PubMed ID: 30778889
[TBL] [Abstract][Full Text] [Related]
18. Can Mapping Algorithms Based on Raw Scores Overestimate QALYs Gained by Treatment? A Comparison of Mappings Between the Roland-Morris Disability Questionnaire and the EQ-5D-3L Based on Raw and Differenced Score Data.
Madan J; Khan KA; Petrou S; Lamb SE
Pharmacoeconomics; 2017 May; 35(5):549-559. PubMed ID: 28063083
[TBL] [Abstract][Full Text] [Related]
19. Performance of PROMIS Global-10 to Legacy Instruments in Patients With Lateral Epicondylitis.
Kahan JB; Kassam HF; Nicholson AD; Saad MA; Kovacevic D
Arthroscopy; 2019 Mar; 35(3):770-774. PubMed ID: 30674423
[TBL] [Abstract][Full Text] [Related]
20. Assessing the health of the general population in England: how do the three- and five-level versions of EQ-5D compare?
Feng Y; Devlin N; Herdman M
Health Qual Life Outcomes; 2015 Oct; 13():171. PubMed ID: 26489956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
